rs10963602 - ADAMTSL1
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment - Unknown journal (n.d.) · Unknown authors · PubMed 32080354
ABSTRACT: Angioedema in the mouth or upper airways is a feared adverse reaction to angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) treatment, which is used for hypertension, heart failure and diabetes complications. This candidate gene and genome-wide association study aimed to identify genetic variants predisposing to angioedema induced by these drugs. The discovery cohort consisted of 173 cases and 4890 controls recruited in Sweden. In the candidate gene analysis, ETV6, BDKRB2, MME, and PRKCQ were nominally associated with angioedema (p < 0.05), but did not pass Bonferroni correction for multiple testing (p < 2.89 × 10−5). In the genome-wide analysis, intronic variants in the calcium-activated potassium channel subunit alpha-1 (KCNMA1)
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
Angioedema risk with ACE inhibitors or ARBs Moderate
ADAMTSL1 variant increases susceptibility to angioedema triggered by ACE inhibitors or ARBs.
Discuss with your doctor before starting or continuing ACE-I or ARB medications.